GlobeNewswire Inc.··Greenwich Lifesciences, Inc.Greenwich LifeSciences Expands FLAMINGO-01 Trial With City of Hope, Advances Breast Cancer Immunotherapy
Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.
GLSIbreast cancerGLSI-100